The use of SANCUSO complies with the NCCN recommendation that choice of antiemetic is based on the emetogenicity of the chemotherapy regimen and individual patient factors (eg, partial or complete bowel obstruction, concomitant drug treatments, including opiates)5
You may have patients with chemotherapy-induced nausea and vomiting (CINV) who are appropriate for SANCUSO. Request a sample at no cost to see if SANCUSO is the right option for your patients.Request Sample
You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.Stay Informed
Sancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
The most common adverse reaction (≥ 3%) is constipation.